ACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index

SAN DIEGO—(BUSINESS WIRE)—Jun. 27, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it has been added to the Russell 1000 Index,effective June 27, 2016. The Russell 1000 Index measures the performanceof the large-cap segment of the U.S. equity universe. It is a subset ofthe Russell 3000 Index and includes approximately 1000 of the largestsecurities based on a combination of their market cap and current indexmembership. All Russell indices are reconstituted on an annual basis toensure new and growing equities are reflected accurately in each index.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.

About FTSE Russell

FTSE Russell is a global index leader and data provider that providesinnovative benchmarking, analytics and data solutions for investorsworldwide. FTSE Russell calculates thousands of indexes that measure andbenchmark markets and asset classes in more than 70 countries, covering98% of the investable market globally. FTSE Russell index expertise andproducts are used extensively by institutional and retail investorsglobally. FTSE Russell is wholly owned by London Stock Exchange Group.For more information, visit www.ftserussell.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, and the benefits to be derivedfrom NUPLAZID™ (pimavanserin) and ACADIA’s product candidates.These statements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including the risks anduncertainties inherent in drug discovery, development, approval andcommercialization, and in collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA’s annual report on Form 10-K for the year ended December 31, 2015as well as ACADIA’s subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:
ACADIA Pharmaceuticals Inc.
LisaBarthelemy, Investor Relations
(858) 558-2871
ir@acadia-pharm.com
or
MediaContact:
Taft and Partners
Ted Deutsch
(609)578-8765
ted@taftandpartners.com